Has Jacob Estes, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,432 in general payments to Jacob Estes, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacob Estes, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacob Estes, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacob Estes, MD

Gynecologic Oncology · New Orleans, LANPI 1255381687

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,500 of the $16,432 with a category attached, or 76.1%. 12 manufacturers reported payments, led by Dilon Technologies, Inc. at 50.4% of the total. 2025 is the largest year on record at $13,439, more than ten times the $571 reported in 2019.

$16,432in general payments, 2019–2025

Across 45 payments — averaging $365.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Dilon Technologies, Inc.$8K
Evologics LLC$5K
Biom'up France SAS$1K
Merck$769
Eisai Inc.$309
Biom'up SA$256
plus $670 from 6 others

What the payments were for

Consulting fees$12,50076%
Food & beverage$3,93224%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Dilon Technologies, Inc.	8	$8,286
Evologics LLC	1	$5,000
Biom'up France SAS	11	$1,142
Merck	12	$769
Eisai Inc.	3	$309
Biom'up SA	2	$256
Myriad Genetic Laboratories, Inc.	1	$138
Tesaro, Inc.	1	$128
Clovis Oncology, Inc.	1	$125
GSK	2	$124
AbbVie	2	$112
Gen-probe Sales & Service, Inc.	1	$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$31,646

Medicare patients

Services billed

186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New Orleans

Katrina WadeNew Orleans$8K
Jessica ShankNew Orleans$4K
David BarringtonNew Orleans$2K
Diogo TorresNew Orleans$2K
Pui ChengNew Orleans$2K
Richard KlineNew Orleans$257
Patricia BralyCovington$130K
Destin BlackShreveport$61K
Andrew GreenShreveport$53K
Amma AgyemangMetairie$2K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →